Extract
Involvement of the respiratory system, the commonest extra-articular manifestation of rheumatoid arthritis (RA), occurs to some extent in a large proportion of patients with RA. Any of the pulmonary compartments can be affected, either secondary to RA itself, or in relation to drug toxicity or opportunistic infection [1]. RA-associated interstitial lung disease (RA-ILD) is an increasingly recognised complication of RA, in many ways similar to idiopathic pulmonary fibrosis [2]. Clinically relevant RA-ILD may be present in up to 10% of patients with RA, and is associated with significant morbidity and mortality [1, 3], with no optimal treatment determined.
Abstract
Methotrexate can induce subacute hypersensitivity pneumonitis, a potentially lethal condition that should lead to drug discontinuation; however, its use does not seem to be associated with increased risk of chronic fibrosing ILD in rheumatoid arthritis https://bit.ly/3sCyjji
Footnotes
Published in volume 57, issue 2 of the European Respiratory Journal on 11 February 2021; republished 15 February 2021 with amendments an author's forename.
Conflict of interest: V. Cottin has received fees for consultancy from Actelion, Boehringer Ingelheim, Bayer, Biogen Idec, GSK, MSD, Novartis, Roche, Sanofi and Galapagos; has received lecture fees from Actelion, Boehringer Ingelheim, Novartis, Roche and Sanofi; has received reimbursement for travel to medical meetings from Actelion, Boehringer Ingelheim and Roche; has received fees for development of educational presentations from Boehringer Ingelheim; has acted as a member of an adjudication committee for Gilead; has received grants to his institution from Boehringer Ingelheim and Roche; and has acted as a member of data and safety monitoring boards for Promedior, Celgene and Galecto.
Conflict of interest: E. Bendstrup has nothing to disclose.
Conflict of interest: P. Bonniaud has nothing to disclose.
Conflict of interest: M. Nasser has nothing to disclose.
Conflict of interest: P. Spagnolo has nothing to disclose.
Conflict of interest: C. Valenzuela has nothing to disclose.
Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape
Support statement: This work was support by the Hospices Civils de Lyon and Université de Lyon. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received January 10, 2021.
- Accepted January 13, 2021.
- ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
